Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)

China · Delayed Price · Currency is CNY

29.33

+1.88 (6.85%)

At close: Aug 4, 2026

SHA:688163 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	197.68	196.21	194.92	190.14	174.22	208.69
Revenue Growth	1.77%	0.66%	2.51%	9.14%	-16.52%	12.46%
Gross Profit	151.72	151.2	149.11	140.3	140.72	172.36
Operating Income	49.61	52.25	46.15	33.22	50.45	82.03
Net Income	48.6	51.79	44.29	38.77	64.2	76.48
Earnings Per Share	0.54	0.48	0.41	0.36	0.63	0.94
EPS Growth	17.81%	17.07%	13.89%	-42.86%	-32.98%	20.51%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	194.49
Overseas	1.72
Total	196.21

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	764.79	808.82	832.58	873.51	933.35	181.03
Total Debt	4.94	5.1	4.3	12.96	13.68	14.35
Net Cash (Debt)	759.85	803.73	828.28	860.55	919.66	166.68
Net Cash Growth	-4.49%	-2.96%	-3.75%	-6.43%	451.75%	40.97%
Net Cash Per Share	8.37	7.45	7.67	7.99	9.02	2.05

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	69.7	60.53	50.25	32.82	67.91	92.29
Capital Expenditures	-78.52	-59.61	-59.37	-28.67	-26.46	-27.61
Free Cash Flow	-8.83	0.93	-9.12	4.15	41.46	64.68
Free Cash Flow Growth	-	-	-	-90.00%	-35.91%	-19.58%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	76.75%	77.06%	76.50%	73.79%	80.77%	82.59%
Operating Margin	25.10%	26.63%	23.68%	17.47%	28.96%	39.30%
Pretax Margin	30.58%	32.72%	25.94%	23.88%	42.50%	42.11%
Profit Margin	24.58%	26.39%	22.72%	20.39%	36.85%	36.65%
FCF Margin	-4.46%	0.47%	-4.68%	2.18%	23.79%	30.99%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.380	0.380	0.320	0.200	0.750	0.900
Dividend Per Share Growth	18.75%	18.75%	60.00%	-73.33%	-16.67%	-
Dividend Yield	1.38%	1.76%	1.86%	1.05%	3.84%	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	54.78	45.49	42.91	55.79	35.55	-
P/FCF Ratio	-	2545.69	-	521.89	55.06	-
PS Ratio	16.06	12.01	9.75	11.38	13.10	-